TRAP1 and neoplasm: In melanoma cells, the inhibition of TRAP1 with gamitrnib (a small-molecule mitochondrial HSP90 inhibitor) in conjunction with treatment with MAPK inhibitors showed a synergistic effect, leading to mitochondrial dysfunction and hinderance of tumor bioenergetics and [5,133].